Novo Nordisk to cut 1,000 jobs to 'prioritize investments in key product launches'

29 September 2016

Around 1,000 jobs are to go at Danish diabetes giant Novo Nordisk (NOV: N), which amounts to nearly 2.4% of its total global workforce.

This action has been described in a Novo Nordisk statement as “one of several actions taken to reduce operating costs as the company faces a challenging competitive environment in 2017, especially in its large US market.”

Novo Nordisk’s share price had dropped by more than 1.5% by mid-afternoon on Thursday following the announcement about the job cuts, which are expected to affect research and development (R&D) and headquarter staff functions, as well as positions in the global commercial organisation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK